Sanofi India Chief Departs, Sets Transformative Path
Outgoing Exec To Lead SeQuent Scientific
Sanofi India's managing director is moving on after an eventful innings that saw the company re-orient operations, moving out of certain non-strategic areas to focus on core therapies. Pre-pandemic early digital adoption appears to have played out well too for the French group’s listed Indian arm.
You may also be interested in...
Sanofi India – in which France’s Sanofi S.A. holds a controlling 60% stake – is to divest its Nutraceuticals business in a deal worth around $80m.
Zentiva is opening a dedicated Indian office in Mumbai to support the Ankleshwar manufacturing facility that it has just acquired from former parent company Sanofi.
Roche debuts ‘responsibly priced’ Phesgo in India. Will the dramatic reduction in treatment time for women with HER2 positive breast cancer and other benefits, including insurance coverage, trigger sharp shifts towards the subcutaneous fixed-dose combination of Perjeta and Herceptin?